Ketotifen

Ketotifen, the active ingredient in Ketotifen, is an antihistamine presented as an oral tablet for oral use. It relieves symptoms of allergic rhinitis, allergic conjunctivitis, and supports management of bronchial asthma by stabilizing mast cells, and may be used for seasonal or perennial allergies.

GNH USA supplies Ketotifen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory‑approved batches for global distribution. All shipments comply with local import regulations and are tracked through secure logistics channels.

Ketotifen is an antihistamine that acts on allergic pathways to reduce symptoms in several related conditions, offering both H1‑receptor blockade and mast‑cell stabilization. - Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge, improving overall nasal comfort and sleep quality. - Allergic conjunctivitis: alleviates eye itching, redness, swelling and tearing, providing clearer vision and comfort. - Bronchial asthma: contributes to asthma control by stabilizing mast cells, decreasing inflammatory mediator release and reducing bronchospasm frequency, potentially lowering the need for rescue inhalers.

Ketotifen may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Drowsiness: mild sedation or sleepiness. - Dry mouth: reduced salivation causing thirst. - Weight gain: modest increase in body weight. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness. Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Hepatotoxicity: signs of liver injury such as jaundice, dark urine or elevated enzymes. - Cardiac arrhythmia: irregular heartbeat, especially in patients with pre‑existing heart conditions. - Blood dyscrasias: rare cases of neutropenia or agranulocytosis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing or dispensing Ketotifen, several safety considerations should be observed to minimize risk. - Assess patient history: evaluate for asthma severity, liver disease or hypersensitivity. - Monitor sedation: advise caution when operating machinery or driving due to possible drowsiness. - Avoid alcohol: concurrent alcohol may enhance central nervous system depression. - Use in pregnancy: only if clearly needed; benefits must outweigh potential risks. - Use in lactation: consider infant exposure through breast milk and assess necessity. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Ketotifen can interact with other medicines, altering its effectiveness or increasing adverse effects. Major Interactions (Avoid): - CYP3A4 inhibitors: strong inhibitors may increase ketotifen plasma levels, raising toxicity risk. - CNS depressants: concurrent use with sedatives or antihistamines can intensify drowsiness. - Monoamine oxidase inhibitors: may increase risk of hypertensive reactions. Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen dry mouth and constipation. - Alcohol: can potentiate sedation and impair coordination. - Other antihistamines: additive antihistaminic effects may increase side‑effect burden. - Theophylline: may reduce bronchodilator response. - Beta‑blockers: may mask tachycardia symptoms.